Alto Neuroscience (NYSE:ANRO) Sees Unusually-High Trading Volume – Still a Buy?

Alto Neuroscience, Inc. (NYSE:ANRO) saw an uptick in trading volume on Monday . Approximately 303,331 shares traded hands during trading, a decline of 19% from the previous session’s volume of 373,522 shares.The stock last traded at $34.9690 and had previously closed at $34.28.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. Wall Street Zen upgraded Alto Neuroscience from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. BTIG Research boosted their price objective on Alto Neuroscience from $28.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Bank of America initiated coverage on Alto Neuroscience in a research report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 target price for the company. Robert W. Baird lowered their target price on Alto Neuroscience from $38.00 to $36.00 and set an “outperform” rating for the company in a research note on Monday, May 18th. Finally, Zacks Research upgraded Alto Neuroscience from a “strong sell” rating to a “hold” rating in a report on Thursday. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $37.25.

Alto Neuroscience Trading Up 4.5%

The firm has a market capitalization of $1.41 billion, a price-to-earnings ratio of -14.90 and a beta of 1.06. The business’s 50-day moving average price is $27.36 and its 200 day moving average price is $23.45. The company has a debt-to-equity ratio of 0.07, a current ratio of 14.85 and a quick ratio of 14.85.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.65) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.08. On average, equities analysts forecast that Alto Neuroscience, Inc. will post -2.68 earnings per share for the current fiscal year.

Institutional Trading of Alto Neuroscience

Large investors have recently modified their holdings of the business. Commodore Capital LP grew its stake in shares of Alto Neuroscience by 49.4% during the first quarter. Commodore Capital LP now owns 2,723,196 shares of the company’s stock valued at $61,217,000 after acquiring an additional 900,000 shares in the last quarter. Vestal Point Capital LP lifted its stake in shares of Alto Neuroscience by 161.6% in the fourth quarter. Vestal Point Capital LP now owns 2,485,000 shares of the company’s stock worth $44,233,000 after acquiring an additional 1,535,000 shares in the last quarter. Perceptive Advisors LLC lifted its stake in shares of Alto Neuroscience by 12.6% in the first quarter. Perceptive Advisors LLC now owns 2,009,893 shares of the company’s stock worth $45,182,000 after acquiring an additional 225,500 shares in the last quarter. Armistice Capital LLC boosted its holdings in Alto Neuroscience by 0.7% in the third quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock valued at $6,577,000 after purchasing an additional 12,000 shares during the last quarter. Finally, Spruce Street Capital LP boosted its holdings in Alto Neuroscience by 494.7% in the first quarter. Spruce Street Capital LP now owns 1,325,210 shares of the company’s stock valued at $29,116,000 after purchasing an additional 1,102,366 shares during the last quarter.

About Alto Neuroscience

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.